Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in Combination With Dasatinib and Quercetin, as a Novel Neoadjuvant Pre-Surgical Therapy for Head and Neck Squamous Cell Carcinoma

Next Previous
Trial Profile

Phase II Trial of Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in Combination With Dasatinib and Quercetin, as a Novel Neoadjuvant Pre-Surgical Therapy for Head and Neck Squamous Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasatinib (Primary) ; Quercetin (Primary) ; Tislelizumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 19 Sep 2024 Planned End Date changed from 1 Dec 2027 to 5 Aug 2028.
  • 19 Sep 2024 Status changed from recruiting to active, no longer recruiting.
  • 31 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top